Minocycline prevents osmotic demyelination associated with aquaresis

Kidney Int. 2014 Nov;86(5):954-64. doi: 10.1038/ki.2014.119. Epub 2014 Apr 23.

Abstract

Overly rapid correction of chronic hyponatremia can cause osmotic demyelination syndrome (ODS). Minocycline protects ODS associated with overly rapid correction of chronic hyponatremia with hypertonic saline infusion in rats. In clinical practice, inadvertent rapid correction frequently occurs due to water diuresis, when vasopressin action suddenly ceases. In addition, vasopressin receptor antagonists have been applied to treat hyponatremia. Here the susceptibility to and pathology of ODS were evaluated using rat models developed to represent rapid correction of chronic hyponatremia in the clinical setting. The protective effect of minocycline against ODS was assessed. Chronic hyponatremia was rapidly corrected by 1 (T1) or 10 mg/kg (T10) of tolvaptan, removal of desmopressin infusion pumps (RP), or administration of hypertonic saline. The severity of neurological impairment in the T1 group was significantly milder than in other groups and brain hemorrhage was found only in the T10 and desmopressin infusion removal groups. Minocycline inhibited demyelination in the T1 group. Further, immunohistochemistry showed loss of aquaporin-4 (AQP4) in astrocytes before demyelination developed. Interestingly, serum AQP4 levels were associated with neurological impairments. Thus, minocycline can prevent ODS caused by overly rapid correction of hyponatremia due to water diuresis associated with vasopressin action suppression. Increased serum AQP4 levels may be a predictive marker for ODS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidiuretic Hormone Receptor Antagonists / toxicity*
  • Aquaporin 4 / blood
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Astrocytes / pathology
  • Behavior, Animal / drug effects
  • Benzazepines / toxicity*
  • Biomarkers / blood
  • Brain / drug effects
  • Brain / metabolism
  • Brain / pathology
  • Brain / physiopathology
  • Chemokines / genetics
  • Chemokines / metabolism
  • Cytokines / genetics
  • Cytokines / metabolism
  • Cytoprotection
  • Deamino Arginine Vasopressin
  • Demyelinating Diseases / blood
  • Demyelinating Diseases / chemically induced
  • Demyelinating Diseases / genetics
  • Demyelinating Diseases / pathology
  • Demyelinating Diseases / prevention & control*
  • Demyelinating Diseases / psychology
  • Disease Models, Animal
  • Diuresis / drug effects*
  • Hyponatremia / blood
  • Hyponatremia / chemically induced
  • Hyponatremia / physiopathology
  • Hyponatremia / therapy*
  • Intracranial Hemorrhages / chemically induced
  • Intracranial Hemorrhages / prevention & control
  • Male
  • Matrix Metalloproteinases / genetics
  • Matrix Metalloproteinases / metabolism
  • Minocycline / pharmacology*
  • Neuroprotective Agents / pharmacology*
  • Osmosis
  • Rats, Sprague-Dawley
  • Saline Solution, Hypertonic / administration & dosage
  • Saline Solution, Hypertonic / toxicity*
  • Sodium / blood
  • Therapeutics / adverse effects*
  • Time Factors
  • Tolvaptan
  • Water-Electrolyte Balance / drug effects

Substances

  • Antidiuretic Hormone Receptor Antagonists
  • Aqp4 protein, rat
  • Aquaporin 4
  • Benzazepines
  • Biomarkers
  • Chemokines
  • Cytokines
  • Neuroprotective Agents
  • Saline Solution, Hypertonic
  • Tolvaptan
  • Sodium
  • Matrix Metalloproteinases
  • Deamino Arginine Vasopressin
  • Minocycline